BioCentury | May 1, 2020
Distillery Therapeutics

The lipids LXA4 and RvD1 as treatment for E. coli pneumonia

...reduced pulmonary inflammation and injury. TARGET/MARKER/PATHWAY: Formyl peptide receptor-like 1 (FPRL1; FPR2); lipoxin A4 (LXA4); resolvin...
...Filep, University of Montreal, Montreal, Quebec email: janos.g.filep@umontreal.ca Claire Quang University of Montreal Formyl peptide receptor-like 1 (FPRL1) (FPR2) Resolvin...
BioCentury | Sep 18, 2019
Distillery Therapeutics

Treating Parkinson's with the resolvin RvD1

...DISEASE CATEGORY: Neurology INDICATION: Parkinson's disease (PD) The resolvin RvD1, a metabolite of omega-3 fatty acids...
...deficits. Next steps include extending RvD1 treatment past 12 months in the rat model. TARGET/MARKER/PATHWAY: Resolvin...
...Biagio Mercuri, University of Rome Tor Vergata, Rome, Italy email: mercurin@med.uniroma2.it Claire Quang University of Rome Tor Vergata Resolvin...
BioCentury | Jul 25, 2019
Translation in Brief

New Therapeutic Targets and Biomarkers: June 2019

...lung cancer. Medical College of Wisconsin Distillery Therapeutics Cancer; colorectal cancer; lung cancer; lymphoma; melanoma Resolvin...
...prevent cancer recurrence due to chemotherapy- or surgery-induced inflammation. Harvard University; Emory University Distillery Therapeutics Resolvin...
BioCentury | Jul 20, 2019
Emerging Company Profile

China Ophthalmology Focus eyes Asia market

Spun out from Lee’s in May and aiming for its first NDA submissions next year, China Ophthalmology Focus is already looking ahead to a Hong Kong IPO and an expansion into other Asian markets with...
BioCentury | Jun 27, 2019
Distillery Therapeutics

Ketorolac and resolvins to prevent cancer recurrence

...alone. Ketorolac is marketed as a generic NSAID for pain and inflammation. TARGET/MARKER/PATHWAY: Cyclooxygenases (COX); Resolvin...
...Sukhatme, Emory University, Atlanta, Ga. email: vsukhatme@emory.edu Claire Quang Acular LS (acuvail 0.45%, ketorolac tromethamine) Emory University Harvard University Cyclooxygenases (COX) Resolvin...
BioCentury | Dec 5, 2017
Distillery Therapeutics

Cancer

...Genentech Inc. unit market the EGFR inhibitor Tarceva to treat NSCLC and pancreatic cancer. TARGET/MARKER/PATHWAY: Resolvin...
...Leviten Erbitux Tarceva Beth Israel Deaconess Medical Center Brigham and Women's Hospital Dana-Farber Cancer Institute Harvard Medical School Resolvin D1 (RvD1) Resolvin D2 (RvD2) Resolvin...
BioCentury | Nov 30, 2017
Preclinical News

Resolvins keep tumor debris from stimulating tumor growth

...resolvin E1 (RvE1). Panigrahy told BioCentury that more research is needed to select the best resolvin...
...with standard cytocidal therapy," and added his team is "evaluating various resolvins as well as resolvin...
...Management LLLP Beth Israel Deaconess Medical Center Brigham and Women's Hospital Harvard Medical School Resolvyx Pharmaceuticals Inc. Resolvin D1 Resolvin D2 (RvD2) Resolvin...
BioCentury | Nov 9, 2016
Distillery Therapeutics

Cardiovascular

...with vehicle. Next steps could include testing RvD1 in additional animal models of atherosclerosis. TARGET/MARKER/PATHWAY: Resolvin...
...Tabas, Columbia University Medical Center, New York, N.Y. email: iat1@columbia.edu Hongjiang Li Brigham and Women's Hospital Harvard Medical School Resolvin...
BioCentury | Oct 27, 2016
Distillery Therapeutics

Neurology

...compared with vehicle. Next steps could include evaluating RvD1 in models of other neuropathies. TARGET/MARKER/PATHWAY: Resolvin...
...China email: zhiyuan.zhang@medizin.uni-tuebingen.de; zzy@njmu.edu.cn CONTACT: Zhiren Zhang, Third Military Medical University, Chongqing, China email: zhangzhiren@yahoo.com Becky Simon Resolvin...
BioCentury | Aug 15, 2016
Finance

Serving returns

China's Ally Bridge Group hit the investment world's radar in 2015 with its audacious move to take CRO WuXi PharmaTech Inc. private. If the firm and its partners can engineer the first fruits of that...
Items per page:
1 - 10 of 44